[Complex assessment of efficacy and tolerance of metoprolol CR/ZOK in treating hypertension].

AIM

To study efficacy and tolerance of betaloc ZOK (Astra-Zeneca, UK) in patients with stage I-II (WHO classification) essential hypertension.

MATERIAL AND METHODS

27 patients were enrolled in the study (13 men and 14 women, mean age 40.6 +/- 1.57 years). Complete physical examination, ambulatory blood pressure monitoring, assessment of central hemodynamics, microcirculation were made before the treatment and on the treatment week 8.

RESULTS

Monotherapy with betalok ZOK (50-100 mg/day) resulted in a significant lowering of mean daily, day and night systolic and diastolic arterial pressure. Variability index was reduced, circadian rhythm of blood pressure did not change. 28% had to take diuretics (arifon or hypotiazide).

CONCLUSION

Betaloc ZOK (50-100 mg) is highly effective in patients with mild to moderate essential hypertension.